Methods of treating cancer

Patent metadata

Field	Value
Publication number	US-9393318-B2
Application number	US-201113073824-A
Country	US
Kind code	B2
Filing date	Mar 28, 2011
Priority date	Mar 29, 2010
Publication date	Jul 19, 2016
Grant date	Jul 19, 2016

Abstract

The present invention provides methods and compositions for treating non-small-cell lung cancer (NSCLC) by administering a) a composition comprising nanoparticles that comprise paclitaxel and an albumin and b) a platinum-based agent (e.g., carboplatin). The present application also provides methods of treating prostate cancer by administering to the individual a) an effective amount of a composition comprising nanoparticles comprising docetaxel and an albumin; and b) an effective amount of a steroid.

First claim

What is claimed is:

1. A method of treating NSCLC in an individual comprising administering to the individual a) an effective amount of a composition comprising nanoparticles comprising paclitaxel and an albumin and b) an effective amount of a platinum-based agent, wherein treatment is based upon the individual i) having squamous cellular carcinoma, and (ii) is at least about 70 years old.

2. The method of claim 1 , wherein the method comprises selecting the individual for treatment based on the individual (i) having squamous cellular carcinoma, and (ii) at least about 70 years old.

3. The method of claim 1 , wherein the effective amount of the composition comprising nanoparticles comprising paclitaxel and albumin is between about 50 mg/m 2 and about 125 mg/m 2 .

4. The method of claim 1 , wherein the composition comprising nanoparticles comprising paclitaxel and albumin is administered weekly.

5. The method of claim 1 , wherein the effective amount of the platinum-based agent is between about AUC=2 and about AUC=6.

6. The method of claim 1 , wherein the platinum-based agent is administered once every three weeks.

7. The method of claim 1 , wherein the effective amount of the composition comprising nanoparticles comprising paclitaxel and albumin is 100 mg/m 2 administered weekly and the effective amount of the platinum-based agent is AUC=6 administered once every three weeks.

8. The method of claim 1 , wherein paclitaxel in the nanoparticles is coated with albumin.

9. The method of claim 1 , wherein the nanoparticles in the composition have an average diameter of no greater than about 200 nm.

10. The method of claim 1 , wherein the NSCLC is Stage IIIB NSCLC or Stage IV NSCLC.

11. The method of claim 1 , wherein the composition comprising nanoparticles comprising paclitaxel and albumin and the platinum-based agent are administered parenterally.

12. The method of claim 11 , wherein the composition comprising nanoparticles comprising paclitaxel and albumin and the platinum-based agent are administered intravenously.

13. The method of claim 1 , wherein the platinum-based agent is carboplatin.

14. The method of claim 1 , wherein the individual is human.

15. The method of claim 1 , wherein the method further comprises administration of thoracic radiation.

16. The method of claim 15 , wherein the effective amount of the composition comprising nanoparticles comprising paclitaxel and albumin is between about 20 mg/m 2 to about 60 mg/m 2 administered weekly, the effective amount of a platinum-based agent is between about AUC=2 to about AUC=6 administered weekly, and the thoracic radiation is between about 25 to about 40 fractions by either 3D conformal or intensity-modulated techniques concurrently.

Assignees

• Desai Neil P
• Soon-Shiong Patrick
• Abraxis Bioscience Llc

Inventors

• Desai Neil P
• Soon-Shiong Patrick

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P11/00

  Drugs for disorders of the respiratory system · CPC title

• A61K33/24

  Heavy metals; Compounds thereof · CPC title

• A61K31/555

  containing heavy metals, e.g. hemin, hematin, melarsoprol · CPC title